We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

MAS:NYSEMasco Corporation Analysis

Data as of 2026-05-19 - not real-time

$64.81

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Masco Corp (MAS) trades at $64.81, sitting above its 20‑day SMA of 70.63 and 50‑day SMA of 65.34, with the price hovering just above the identified support at $63.25. The RSI of 40 and a bearish MACD histogram (‑1.03) suggest momentum is fading, while the 30‑day volatility of 47% and a beta of 1.15 indicate a relatively aggressive price swing. Fundamentally, the stock appears overvalued – the DCF fair value of $48.24 is well below the market price, yielding a downside potential of roughly 24.5%, despite a modest PE of 16 versus an industry average of 29.3. The company posted a 6.5% revenue growth YoY, with operating margin expanding to 16.5% and operating profit up 13% in Q1 2026, supported by a strong cash flow ($1.10 B operating, $0.74 B free) and a sustainable dividend yield of 1.95% backed by a 30.9% payout ratio. However, the balance sheet raises concerns: a massive debt load of $3.30 B, a debt‑to‑equity ratio exceeding 12,000%, and a negative book value per share (‑$1.20) signal financial leverage risk. Recent material news – a $300 M accelerated share repurchase agreement and a quarterly dividend declaration of $0.32 per share – provide short‑term price support and underscore management’s confidence in cash generation.
Overall, MAS sits at a crossroads where technical weakness and valuation premium clash with solid earnings momentum and dividend appeal. Investors should weigh the bearish technical signals and leverage risk against the company’s growth trajectory, dividend stability, and share‑repurchase program when forming a view.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 5/10

Key Factors

  • Bearish MACD and neutral RSI indicating limited upside
  • Price near support but technical momentum weakening
  • Decreasing volume suggesting lower short‑term interest

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • Strong Q1 earnings growth and expanding operating margins
  • $300 M accelerated share repurchase providing price support
  • Attractive dividend yield with a low payout ratio

Long Term

> 3 years
Neutral
Model confidence: 6/10

Key Factors

  • High leverage and negative book value creating balance‑sheet risk
  • Valuation gap between market price and DCF fair value
  • Sustained dividend and consistent cash‑flow generation

Key Metrics & Analysis

Financial Health

Revenue Growth6.50%
Profit Margin10.90%
P/E Ratio16.0
ROE8457.14%
ROA15.68%
Debt/Equity12229.63
P/B Ratio-54.0
Op. Cash Flow$1.1B
Free Cash Flow$738.5M
Industry P/E29.4

Technical Analysis

TrendNeutral
RSI40.0
Support$63.25
Resistance$76.10
MA 20$70.63
MA 50$65.34
MA 200$67.74
MACDBearish
VolumeDecreasing
Fear & Greed Index89.57

Valuation

Fair Value$48.24
Target Price$80.67
Upside/Downside24.48%
GradeOvervalued
TypeBlend
Dividend Yield1.95%

Risk Assessment

Beta1.15
Volatility47.44%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.